CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy (original) (raw)

• Andersson C, Blennow K, Almkvist O et al (2008) Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 29:1466–1473
  Article CAS PubMed Google Scholar
• Andreasen N, Hesse C, Davidsson P et al (1999) Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56:673–680
  Article CAS PubMed Google Scholar
• Andreasen N, Minthon L, Clarberg A et al (1999) Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53:1488–1494
  CAS PubMed Google Scholar
• Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4:147–155
  Article PubMed Google Scholar
• Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin Neurol Neurosurg 107:165–173
  Article PubMed Google Scholar
• Blennow K, Wallin A, Agren H et al (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231–245
  Article CAS PubMed Google Scholar
• Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol 24:87–97
  Article CAS PubMed Google Scholar
• Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613
  Article CAS PubMed Google Scholar
• Blennow K, Vanmechelen E (2003) CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 61:235–242
  Article CAS PubMed Google Scholar
• Blennow K (2005) CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5:661–672
  Article CAS PubMed Google Scholar
• Blennow K, Zetterberg H, Minthon L et al (2007) Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neurosci Lett 419:18–22
  Article CAS PubMed Google Scholar
• Bouwman FH, van der Flier WM, Schoonenboom NS et al (2007) Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69:1006–1011
  Article CAS PubMed Google Scholar
• Bouwman FH, Schoonenboom NS, Verwey NA et al (2009) CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging 30:1895–1901
  Article CAS PubMed Google Scholar
• Degerman Gunnarsson M, Kilander L, Basun H et al (2007) Reduction of phosphorylated tau during memantine treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 24:247–252
  Article CAS PubMed Google Scholar
• de Leon MJ, Segal S, Tarshish CY et al (2002) Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 333:183–186
  Article PubMed Google Scholar
• de Leon MJ, DeSanti S, Zinkowski R et al (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27:394–401
  Article PubMed Google Scholar
• Diniz BS, Pinto JA Jr, Forlenza OV (2007) Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9:1–11
  Google Scholar
• Ewers M, Buerger K, Teipel SJ et al (2007) Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69:2205–2212
  Article CAS PubMed Google Scholar
• Formichi P, Battisti C, Radi E et al (2006) Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer’s disease. J Cell Physiol 208:39–46
  Article CAS PubMed Google Scholar
• Frankfort SV, Tulner LR, van Campen JP et al (2008) Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 3:123–131
  Article CAS PubMed Google Scholar
• Greenberg SG, Davies PA (1990) Preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87:5827–5831
  Article CAS PubMed Google Scholar
• Hampel H, Buerger K, Kohnken R et al (2001) Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49:545–546
  Article CAS PubMed Google Scholar
• Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234
  Article CAS PubMed Google Scholar
• Herukka SK, Hallikainen M, Soininen H et al (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64:1294–1297
  CAS PubMed Google Scholar
• Hrnkova M, Zilka N, Minichova Z et al (2007) Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res 1130:206–213
  Article CAS PubMed Google Scholar
• Hu YY, He SS, Wang X et al (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160:1269–1278
  CAS PubMed Google Scholar
• Hulstaert F, Blennow K, Ivanoiu A et al (1999) Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 52:1555–1562
  CAS PubMed Google Scholar
• Iqbal K, Flory M, Khatoon S et al (2005) Subgroups of Alzheimer’s disease based on cerebrospinal fluid molecular markers. Ann Neurol 58:748–757
  Article CAS PubMed Google Scholar
• Ishiguro K, Ohno H, Arai H et al (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci Lett 270:91–94
  Article CAS PubMed Google Scholar
• Kanai M, Matsubara E, Isoe K et al (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44:17–26
  Article CAS PubMed Google Scholar
• Kluver H, Barrera E (1953) A method for the combined staining of cells and fibers in the nervous system. J Neuropathol Exp Neurol 12:400–403
  Article CAS PubMed Google Scholar
• Kohnken R, Buerger K, Zinkowski R et al (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett 287:187–190
  Article CAS PubMed Google Scholar
• Korenova M, Zilka N, Stozicka Z et al (2009) NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy. J Neurosci Methods 177:108–114
  Article PubMed Google Scholar
• Koson P, Zilka N, Kovac A et al (2008) Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur J Neurosci 28:239–246
  Article PubMed Google Scholar
• Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80:966–975
  Article CAS PubMed Google Scholar
• Montine TJ, Beal MF, Cudkowicz ME et al (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562–565
  CAS PubMed Google Scholar
• Pratico D, Clark CM, Lee VM et al (2000) Increased 8, 12-iso-iPF2alpha-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809–812
  Article CAS PubMed Google Scholar
• Sunderland T, Wolozin B, Galasko D et al (1999) Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 46:750–755
  Article CAS PubMed Google Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P et al (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52
  Article CAS PubMed Google Scholar
• Vemuri P, Wiste HJ, Weigand SD et al (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73:287–293
  Article CAS PubMed Google Scholar
• Wallin AK, Blennow K, Andreasen N et al (2006) CSF biomarkers for Alzheimer’s disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21:131–138
  Article CAS PubMed Google Scholar
• Zetterberg H, Pedersen M, Lind K et al (2007) Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 12:255–260
  CAS PubMed Google Scholar
• Zilka N, Filipcik P, Koson P et al (2006) Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 580:3582–3588
  Article CAS PubMed Google Scholar